Mesoblast (NASDAQ:MESO) Stock Price Up 6.6%

Mesoblast Limited (NASDAQ:MESO - Get Free Report) traded up 6.6% during trading on Tuesday . The stock traded as high as $6.48 and last traded at $6.48. 1,516,520 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 2,068,363 shares. The stock had previously closed at $6.08.

Analysts Set New Price Targets

Several research analysts have commented on the stock. StockNews.com upgraded shares of Mesoblast from a "sell" rating to a "hold" rating in a report on Monday, March 4th. Cantor Fitzgerald restated an "overweight" rating on shares of Mesoblast in a report on Friday, January 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $13.67.

Mesoblast Trading Up 8.4 %

The company's 50 day moving average is $2.41 and its 200-day moving average is $2.34. The company has a market capitalization of $669.08 million, a P/E ratio of -5.88 and a beta of 3.59.

Institutional Trading of Mesoblast

Several institutional investors have recently bought and sold shares of the company. Vident Investment Advisory LLC grew its position in Mesoblast by 12.8% during the 4th quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company's stock valued at $82,000 after purchasing an additional 3,191 shares during the last quarter. Lazari Capital Management Inc. boosted its holdings in shares of Mesoblast by 9.3% during the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company's stock valued at $116,000 after acquiring an additional 8,000 shares during the last quarter. EWA LLC purchased a new stake in shares of Mesoblast during the 1st quarter valued at about $40,000. Envestnet Asset Management Inc. boosted its holdings in shares of Mesoblast by 99.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,008 shares of the company's stock valued at $76,000 after acquiring an additional 12,954 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Mesoblast by 55.0% during the 2nd quarter. Wells Fargo & Company MN now owns 52,813 shares of the company's stock valued at $206,000 after acquiring an additional 18,747 shares during the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.